Financings
Allon Therapeutics Inc. raised $10.1 million in a private placement of stock and warrants.
DARA Biosciences Inc. raised $10.3 million through a public offering of preferred stock and warrants.
iTeos Therapeutics SA raised $3.9 million in a Series A round for cancer immunomodulators.
Pacira Pharmaceuticals Inc. secured a $27.5 million debt financing facility through Oxford Finance.
Raptor Pharmaceutical Corp. set up a $40 million at-the-market deal with Cowen and Co. LLC.
Supernus Pharmaceuticals Inc. raised $50 million in its initial public offering.
Deals
Abbott paid $110 million to acquire kidney drug AP214 from Action Pharma A/S.
AnaptysBio Inc. is partnering with Gilead Sciences Inc. to develop antibody therapeutics.
Axerion Therapeutics Inc. entered an Alzheimer's research deal with AstraZeneca plc.
Caisson Biotech LLC licensed its heparosan-based drug delivery platform to Novo Nordisk A/S.
EUSA Pharma Ltd. is being acquired by Jazz Pharmaceuticals Inc. for $700 million cash.
Tolero Pharmaceuticals Inc. licensed Btk drugs from MannKind Corp. for $130 million.
. . . And More
See BioWorld Today for coverage of the American Academy of Neurology annual meeting and the New York Biotechnology Association annual meeting.
Actelion Ltd.'s macitentan hit the endpoint in a Phase III trial for pulmonary arterial hypertension.
Amgen Inc. got a complete response letter for Xgeva (denosumab) in the prevention of bone metastases.
Johnson & Johnson, of New Brunswick, N.J., won FDA approval of Levaquin (levofloxacin) for plague.
Novartis AG won FDA approval of Afinitor (everolimus) for tuberous sclerosis complex-related non-cancerous kidney tumors.
Protalix BioTherapeutics Inc. and Pfizer Inc. got FDA approval of Elelyso (taliglucerase alfa) in Gaucher.
Targacept Inc.'s partnership with AstraZeneca plc on TC-5214 was terminated.
Vivus Inc.'s erectile dysfunction drug Stendra (avanafil) gained FDA approval.